Brigatinib
Brand names: ALUNBRIG
Description
Brigatinib is a tyrosine kinase inhibitor that targets ALK, c-ros oncogene 1 (ROS1), and insulin-like growth factor 1 receptor (IGF-1R). It is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
ATC Classification
Code
Title
Category
Related medicines
2D Molecule Structure
Unique Ingredient Identifier (UNII)
HYW8DB273J - BRIGATINIB
SNOMED-CT
736634002 - Brigatinib (substance)